A Phase 2, multicenter, open-label study evaluating the response rate (CR, CRh and CRi) as well as the safety, toxicity and pharmacokinetics of BTX-A51 in combination with azacitidine in patients with R/R AML
Latest Information Update: 27 Mar 2024
At a glance
- Drugs BTX A51 (Primary) ; Azacitidine
- Indications Acute myeloid leukaemia
- Focus Adverse reactions; Therapeutic Use
Most Recent Events
- 27 Mar 2024 New trial record